Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) post-primary treatment for advanced epithelial ovarian cancer (EOC) is feasible and safe.
No conversions to laparotomy or serious perioperative complications occurred, highlighting minimally invasive benefits.
Grade 3/4 adverse events were limited to temporary myelosuppression, resolving within six weeks.
Patient-reported quality of life improved post-procedure, supporting tolerability of consolidation laparoscopic HIPEC.
